drugset / Trial / NCT06490081
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression
Timeline
- Start
- 2024-06-26
- Primary completion
- 2026-01-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trilaciclib | Unknown | — | — |